N/A
N=1,463
Virtual Gout Clinic
Gout
Bottom Line
View on ClinicalTrials.gov: NCT02790463 ↗Enrolled (actual)
1,463
Serious AEs
0.1%
Results posted
Nov 2019
Primary outcome: Primary: sUA < 6.0 mg/dl at 1 Year — 117; 204 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Pharmacist-Led Intervention (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Alabama at Birmingham
- Primary completion
- Sep 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY sUA < 6.0 mg/dl at 1 Year |
117; 204 | — |
| PRIMARY Adherence to Medication |
250; 341 | — |
Summary
The overarching goal of the investigators project is to identify best practices in gout and hyperuricemia management, translate these evidence-based practices into a highly generalizable strategy for optimal delivery of gout care, and implement and evaluate such a strategy in a large, population-based healthcare setting. With the use of novel but readily-accessible technology, the investigators will examine the use of a novel, large-scale, and relatively low-cost pharmacy-based intervention, with the goal of optimizing urate lower therapy (ULT) in chronic gout treatment.
Eligibility Criteria
Inclusion Criteria
- At least one prior International Classification of Disease (ICD) 9 code for gout (274.xx)
- Received a new prescription for allopurinol, defined as no prior allopurinol prescription in the preceding 12 months
Exclusion Criteria
- No prior ICD9 code for gout (274.xx)
- Did not receive a new prescription for allopurinol, defined as no prior allopurinol prescription in the preceding 12 months
Data sourced from ClinicalTrials.gov (NCT02790463). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.